Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-VISTA monoclonal antibody SNS-101

A conditionally active, pH-sensitive human immunoglobulin (Ig) G1 monoclonal antibody directed against the negative immune checkpoint regulatory protein V-domain Ig suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative immune checkpoint regulatory and antineoplastic activities. Upon administration, anti-VISTA monoclonal antibody SNS-101 selectively targets, binds to and blocks the VISTA checkpoint within a low, acidic pH tumor microenvironment (TME). This prevents the interaction of VISTA with its receptor PSGL-1 on T cells, inhibits VISTA-mediated signaling, decreases the presence of monocytic myeloid-derived suppressor cells (MDSCs), increases the presence of natural killer cells (NKs), activates dendritic cells (DCs) and abrogates VISTA-induced suppression of T-lymphocyte immune responses. This enhances cytotoxic T-cell infiltration, proliferation, and activation within the TME, increases cytokine production by T cells, and inhibits tumor cell growth. VISTA, a negative checkpoint molecule of immune activation, is highly expressed on myeloid cells, T cells and in several tumor types. It plays a key role in the suppression of T-cell function and tumor immunosuppression.
Synonym:conditionally active VISTA-blocking antibody SNS-101
VISTA-blocking monoclonal antibody SNS-101
Code name:SNS 101
SNS-101
SNS101
Search NCI's Drug Dictionary